50% of Contact Lens Wearers Suffer Dry Eye but Few Viable Solutions Exist

Contact lens discomfort, primarily driven by dry eye symptoms, is the number one reason people stop wearing contacts. Research shows that 50.1% of contact lens wearers experience dry eye symptoms, compared to 21.7% of non-wearers. Approximately 70% of wearers report discomfort by the end of the day. The global contact lens dropout rate is 15-20% annually, with the pooled mean across studies at 21.7%, and discomfort is the primary driver for established wearers. So what? For the roughly 22 million Americans experiencing contact-lens-related dry eye, the daily reality is a choice between blurry, gritty, irritated eyes by 4 PM or switching to glasses. Rewetting drops provide temporary relief measured in minutes. Premium daily disposable lenses marketed as 'moisture-rich' cost 2-3x more than standard dailies and provide marginal improvement. For many wearers, the discomfort is not bad enough to stop wearing contacts entirely but is bad enough to be a constant low-grade annoyance that degrades quality of life every single day. The deeper problem is that the contact lens industry has spent decades optimizing for oxygen permeability and convenience (daily disposables, extended wear) while making only incremental progress on comfort. Lens materials have improved, but the fundamental issue — placing a polymer disc on a mucous membrane that needs constant hydration — has not been solved. Artificial tear formulations are largely unchanged in decades. Why does this persist? The contact lens market is dominated by four manufacturers (Johnson & Johnson, Alcon, CooperVision, Bausch + Lomb) who compete primarily on brand, rebates, and doctor relationships rather than on breakthrough comfort technology. The R&D pipeline favors incremental material improvements (silicone hydrogel variants) over fundamentally new approaches because incremental changes are cheaper to develop and easier to get through FDA clearance. Dry eye itself is a complex, multifactorial condition involving meibomian gland dysfunction, tear film instability, and ocular surface inflammation, which makes it genuinely hard to solve with lens design alone. But the industry's incentive structure does not reward solving it: a wearer who drops out of contacts due to discomfort is replaced by a new wearer entering the market, so churn is tolerated rather than treated as a crisis.